Bokf Na trimmed its stake in Boston Scientific Co. (NYSE:BSX – Free Report) by 13.9% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 2,688 shares of the medical equipment provider’s stock after selling 434 shares during the quarter. Bokf Na’s holdings in Boston Scientific were worth $183,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Vanguard Group Inc. grew its holdings in Boston Scientific by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider’s stock worth $8,728,221,000 after buying an additional 1,988,082 shares in the last quarter. Primecap Management Co. CA grew its stake in shares of Boston Scientific by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 37,905,659 shares of the medical equipment provider’s stock worth $2,191,326,000 after purchasing an additional 550,490 shares in the last quarter. Norges Bank acquired a new position in shares of Boston Scientific during the fourth quarter valued at $930,626,000. Capital World Investors raised its stake in shares of Boston Scientific by 69.9% during the first quarter. Capital World Investors now owns 16,008,085 shares of the medical equipment provider’s stock valued at $1,096,394,000 after purchasing an additional 6,588,256 shares in the last quarter. Finally, Putnam Investments LLC lifted its holdings in Boston Scientific by 110.5% in the fourth quarter. Putnam Investments LLC now owns 13,067,570 shares of the medical equipment provider’s stock worth $755,436,000 after purchasing an additional 6,859,280 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Insider Buying and Selling at Boston Scientific
In other Boston Scientific news, EVP Eric Francis Yves Thepaut sold 12,931 shares of Boston Scientific stock in a transaction on Friday, May 10th. The shares were sold at an average price of $74.14, for a total transaction of $958,704.34. Following the completion of the sale, the executive vice president now owns 31,422 shares of the company’s stock, valued at approximately $2,329,627.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Eric Francis Yves Thepaut sold 12,931 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $74.14, for a total transaction of $958,704.34. Following the completion of the sale, the executive vice president now directly owns 31,422 shares of the company’s stock, valued at approximately $2,329,627.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 3,946 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total value of $286,874.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,854 shares of company stock worth $3,366,983. 0.50% of the stock is currently owned by company insiders.
Boston Scientific Stock Performance
Shares of BSX stock opened at $74.03 on Wednesday. The stock’s fifty day simple moving average is $76.46 and its 200-day simple moving average is $70.69. The company has a market capitalization of $108.61 billion, a price-to-earnings ratio of 62.21, a P/E/G ratio of 2.55 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $79.43.
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.04. The company had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 EPS. On average, sell-side analysts predict that Boston Scientific Co. will post 2.4 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, April 25th. The Goldman Sachs Group started coverage on Boston Scientific in a research note on Thursday, May 30th. They set a “buy” rating and a $90.00 price target for the company. JPMorgan Chase & Co. upped their price objective on Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Truist Financial lifted their target price on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Finally, Wells Fargo & Company upped their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Two investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $84.76.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Recommended Stories
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Boston Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.